Jeanne Frances Taylor Hecht
About Jeanne Frances Taylor Hecht
Data last updated:
Jeanne Frances Taylor Hecht is a Director at Veeda Clinical Research Limited (since 2021). The companies operate in Pharma. Veeda Clinical Research Limited reported revenue of ₹621 Cr (FY 2025). Earlier, Jeanne Frances Taylor Hecht was a Director at Veeda Clinical Research Limited (2021–2026).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Veeda Clinical Research Limited U73100GJ2004PLC044023 | Director | 01 Jul 2021 | 2004 | ₹621 Cr (FY 2025) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Veeda Clinical Research Limited U73100GJ2004PLC044023 | Director | 01 Jul 2021 | 2004 | ₹621 Cr (FY 2025) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Jeanne Frances Taylor Hecht
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Jeanne Frances Taylor Hecht
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jeanne Frances Taylor Hecht
Jeanne Frances Taylor Hecht currently holds 1 directorship: Veeda Clinical Research Limited (Director, since 01 Jul 2021, revenue ₹621 Cr (FY 2025)).
Jeanne Frances Taylor Hecht was first appointed on 01 Jul 2021 as Director at Veeda Clinical Research Limited.
Jeanne Frances Taylor Hecht held 1 earlier board appointment: Veeda Clinical Research Limited (Director, 01 Jul 2021 to 01 Jul 2026).
The current boards of Jeanne Frances Taylor Hecht's companies include Apurva Bhupendra Shah (Veeda Clinical Research Limited), Binoy Hasmukh Gardi (Veeda Clinical Research Limited), Binoy Hasmukh Gardi (Veeda Clinical Research Limited), David Paul Kenny (Veeda Clinical Research Limited), Georgios Kouvatseas (Veeda Clinical Research Limited), Ioannis Orfanidis (Veeda Clinical Research Limited), among others.